Jin-Xiong She, PhD, Georgia Research Alliance (GRA) eminent scholar, and his team at the Medical College of Georgia (MCG) in Augusta have launched a biotech company, Jinfiniti Biosciences LLC, to improve the diagnosis and treatment of diabetes and cancer. She, director of the MCG Center for Biotechnology and Genomic Medicine, is president and CEO of the company, which is housed in MCG’s Life Sciences Business Development Center, a turnkey incubator for start-ups. Jinfiniti provides a variety of high-throughput scientific services, including nucleic acid isolation, genomic analysis, antibody production, immunoassays, medicinal chemistry, and toxicity evaluation for academic and pharmaceutical institutions. The company also is developing biomarkers that will enable simple urine or blood tests for early disease detection and monitoring of treatment outcomes. Additionally, the company is developing drugs and companion biomarkers for personalized medicine.

Charles Nawrot, MCG associate vice president for technology transfer and economic development, calls She’s company a logical outgrowth of his research, which focuses on translational studies such as identifying high-risk genes for type 1 diabetes and studying how they interact with the environment to cause disease in humans. She’s company is part of the GRA VentureLab program, established in 2002 to build companies from the research at GRA’s six affiliated universities.

Source:  GRA Perspectives

Posted July 28th, 2010 under Tech Transfer

Write a comment